Please enable JS

Investors & Media

SEC Filings

Form PRE 14A
CRISPR THERAPEUTICS AG filed this Form PRE 14A on 04/02/2018
Document Outline
Entire Document (890.5 KB)
Subdocument 1 - PRE 14A - PRE 14A
Page 1 - UNITED STATES
Page 2 - CRISPR THERAPEUTICS AG
Page 3 - 6.a Binding vote on total non-performance-related compensation for members of the Board of Directors
Page 4 - 6.e Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeti
Page 5 - N/A
Page 6 - Important Notice Regarding Internet Availability of Proxy Materials:
Page 7 - TABLE OF CONTENTS
Page 8 - CRISPR THERAPEUTICS AG
Page 9 - N/A
Page 10 - IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
Page 11 - If your shares are held in street name,
Page 12 - Regardless of whether your shares are held in street name, you are welcome to attend the 2018 Annual
Page 13 - If your shares are held in street name,
Page 14 - BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
Page 15 - Nominees for Election as Member
Page 16 - Kurt von Emster, CFA, Director:
Page 17 - Code of Business Conduct and Ethics
Page 18 - Board Determination of Independence
Page 19 - Committees of the Board of Directors
Page 20 - Compensation Committee
Page 21 - Nominating and Corporate Governance Committee
Page 22 - Shareholder Nominations
Page 23 - Related Person Transactions
Page 24 - Piggyback Registration Rights
Page 25 - N/A
Page 26 - EXECUTIVE COMPENSATION
Page 27 - Executive Compensation
Page 28 - Narrative Disclosure to Summary Compensation Table
Page 29 - Outstanding Equity Awards at Year-End
Page 30 - Rodger Novak.
Page 31 - Michael Tomsicek.
Page 32 - Other Agreements
Page 33 - Section 401(k) Plan
Page 34 - DIRECTOR COMPENSATION
Page 35 - N/A
Page 36 - SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
Page 37 - REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
Page 38 - MATTERS TO BE VOTED ON
Page 39 - Proposal 2: Approval of the Appropriation of Financial Results
Page 40 - Proposal 3: Discharge of the Members of the Board of Directors and Executive Committee
Page 41 - Proposal 4: Election of Eight Directors
Page 42 - 4.e Re-election of Pablo Cagnoni, M.D.
Page 43 - Proposal 5: Re-Election of Members of the Compensation Committee
Page 44 - Proposal 6: Approval of the Compensation for the Board of Directors and the Members of the Executive
Page 45 - 6.e Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeti
Page 46 - Proposal 7: Increase of the Conditional Share Capital for Employee Benefit Plans
Page 47 - italics
Page 48 - Proposal 8: Approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan
Page 49 - Rationale for Share Increase
Page 50 - Stock Appreciation Rights.
Page 51 - Unrestricted Stock Awards.
Page 52 - Tax Aspects Under the Code
Page 53 - Non-Qualified Options.
Page 54 - Proposal 9: Approval of Increasing the Maximum Number of Authorized Share Capital and Extending the
Page 55 - Proposal 10: Re-Election of Independent Voting Rights Representative
Page 56 - Proposal 11: The re-election of Ernst Young AG as our statutory auditor for the term office of one y
Page 57 - Pre-Approval Policies and Procedures
Page 58 - STOCK OWNERSHIP AND REPORTING
Page 59 - N/A
Page 60 - N/A
Page 61 - Section 16(a) Beneficial Ownership Reporting Compliance
Page 62 - N/A
Page 63 - OTHER MATTERS
Page 64 - Appendix A
Page 65 - Incentive Stock Option
Page 66 - Ten Percent Owner
Page 67 - Delegation of Authority to Grant Awards
Page 68 - Reserved
Page 69 - ELIGIBILITY
Page 70 - Wertrechte
Page 71 - RESTRICTED STOCK AWARDS
Page 72 - Election to Receive Restricted Stock Units in Lieu of Compensation
Page 73 - TRANSFERABILITY OF AWARDS
Page 74 - SECTION
Page 75 - GENERAL PROVISIONS
Page 76 - INCENTIVE STOCK OPTION AGREEMENT
Page 77 - Termination of Employment
Page 78 - Termination for Cause
Page 79 - Integration
Page 80 - NON-QUALIFIED STOCK OPTION AGREEMENT
Page 81 - Termination of Employment
Page 82 - Termination for Cause
Page 83 - Notices
Page 84 - NON-QUALIFIED STOCK OPTION AGREEMENT
Page 85 - Termination as Director
Page 86 - Incorporation of Plan
Page 87 - RESTRICTED STOCK AWARD AGREEMENT
Page 88 - Dividends
Page 89 - Notices
Page 90 - RESTRICTED STOCK UNIT AWARD AGREEMENT
Page 91 - Tax Withholding
Page 92 - RESTRICTED STOCK UNIT AWARD AGREEMENT
Page 93 - Section 409A of the Code.
Page 94 - CRISPR Therapeutics AG
Page 95 - ANNUAL MEETING PROXY CARD
Page 96 - 6.b Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meetin
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet